

Table 3. Association of Cyclooxygenase-2 Inhibitor and Nonselective Nonsteroidal Anti-Inflammatory Drug Use within the Index Week with the Odds of Nonfatal Myocardial Infarction*

Drug Use	Case-Patients, <i>n</i> (%)	Controls, <i>n</i> (%)	Unadjusted Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI) [†]
Overall	1718 (100)	6800 (100)		
No NSAID use	1354 (78.8)	4491 (66.0)	1.0	1.0
Nonselective NSAID use	319 (18.6)	2144 (31.5)	0.49 (0.43–0.56)	0.61 (0.52–0.71)
All COX-2 inhibitors	45 (2.6)	165 (2.4)	0.90 (0.65–1.26)	0.73 (0.49–1.07)
Rofecoxib use only	27 (1.6)	78 (1.2)	1.15 (0.74–1.79)	1.16 (0.70–1.93)
Celecoxib use only	18 (1.0)	87 (1.3)	0.69 (0.41–1.14)	0.43 (0.23–0.79)
Stratified by aspirin use				
Non-aspirin users‡	1140 (100)	4991 (100)		
No NSAID use	907 (79.5)	3196 (64.0)	1.0	1.0
Nonselective NSAID use	206 (18.1)	1679 (33.6)	0.43 (0.37–0.51)	0.55 (0.46–0.66)
All COX-2 inhibitors	27 (2.4)	116 (2.3)	0.82 (0.54–1.25)	0.68 (0.41–1.11)
Rofecoxib use only	17 (1.5)	53 (1.1)	1.13 (0.65–1.96)	1.19 (0.64–2.22)
Celecoxib use only	10 (0.9)	63 (1.3)	0.56 (0.29–1.09)	0.35 (0.16–0.76)
Aspirin users‡	578 (100)	1809 (100)		
No NSAID use	447 (77.3)	1295 (71.6)	1.0	1.0
Nonselective NSAID use	113 (19.6)	465 (25.7)	0.70 (0.56–0.89)	0.77 (0.59–1.00)
All COX-2 inhibitors	18 (3.1)	49 (2.7)	1.06 (0.61–1.84)	0.88 (0.45–1.72)
Rofecoxib use only	10 (1.7)	25 (1.4)	1.16 (0.55–2.43)	1.14 (0.47–2.77)
Celecoxib use only	8 (1.4)	24 (1.3)	0.97 (0.43–2.16)	0.67 (0.25–1.80)

* COX-2 = cyclooxygenase-2; NSAID = nonsteroidal anti-inflammatory drug.

† Adjusted for age; sex; race; smoking; insurance; number of physician visits in the previous year; family history of coronary disease; body mass index; activity score; year; previous angina or coronary disease; history of diabetes, hypertension, heart failure, and hypercholesterolemia; and use of statins, β -blockers, calcium-channel blockers, angiotensin-converting enzyme inhibitors, and diuretics.

‡ Adjusted for all variables above, except aspirin use.